{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:02:43Z","timestamp":1791806563871,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejmech.2022.114533","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:19:51Z","timestamp":1655385591000},"page":"114533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Recent advances in the development of EGFR degraders: PROTACs and LYTACs"],"prefix":"10.1016","volume":"239","author":[{"given":"Dawei","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bizhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liquan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-3355","authenticated-orcid":false,"given":"Jingyan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114533_bib1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fonc.2019.01308","article-title":"Epidermal growth factor receptor family and its role in gastric cancer","volume":"9","author":"Arienti","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2022.114533_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100934","article-title":"Long term follow-up of EGFR mutated NSCLC cases","volume":"14","author":"Rennert","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejmech.2022.114533_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1186\/s12885-018-4774-y","article-title":"EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis","volume":"18","author":"Benbrahim","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2022.114533_bib4","first-page":"43","article-title":"Cancer statistics","volume":"57","author":"Ahmedin Jemal 1","year":"2007","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2022.114533_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102906","article-title":"Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC","volume":"148","author":"Baraibar","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2022.114533_bib6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jtho.2017.06.006","article-title":"Comprehensive analysis of EGFR-mutant abundance and its effect on efficacy of EGFR TKIs in advanced NSCLC with EGFR mutations","volume":"12","author":"Li","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2022.114533_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jtho.2019.03.022","article-title":"Advanced-stage non\u2013small cell lung cancer: advances in thoracic oncology 2018","volume":"14","author":"Remon","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2022.114533_bib8","first-page":"1","article-title":"Survival outcomes of nonsmall cell lung cancer patients treated with afatinib who are affected by early adverse events","author":"Logan","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2022.114533_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114533_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2017.05.027","article-title":"Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance","volume":"142","author":"Patel","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112995","article-title":"The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation","volume":"210","author":"He","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd1445","article-title":"Cetuximab","volume":"3","author":"Graham","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114533_bib13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nrd2204","volume":"5","author":"Saltz","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114533_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114533_bib15","first-page":"377","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.ejmech.2022.114533_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cbpa.2019.11.012","article-title":"Targeted protein degradation: current and future challenges","volume":"56","author":"Hanzl","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114533_bib17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","article-title":"Targeted protein degradation: a promise for undruggable proteins","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114533_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114533_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114533_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/med.21877","article-title":"Strategies for designing proteolysis targeting chimaeras (PROTACs)","author":"He","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2022.114533_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2022.114533_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114533_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2022.114533_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1067\/mcn.2002.125874","article-title":"The epidermal growth factor receptor: a new target for anticancer therapy","volume":"26","author":"Grunwald","year":"2002","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.ejmech.2022.114533_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.biophys.37.032807.125829","article-title":"Structure-based view of epidermal growth factor receptor regulation","volume":"37","author":"Ferguson","year":"2008","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.ejmech.2022.114533_bib26","first-page":"2958","article-title":"A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114533_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41388-020-01510-w","article-title":"The next tier of EGFR resistance mutations in lung cancer","volume":"40","author":"Tumbrink","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114533_bib28","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1200\/JCO.2007.12.1178","article-title":"Structure and clinical relevance of the epidermal growth factor receptor in human cancer","volume":"26","author":"Kumar","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114533_bib29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbapap.2009.12.010","article-title":"Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer","volume":"1804","author":"Eck","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2022.114533_bib30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2022.114533_bib31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114533_bib32","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/annonc\/mdx288","article-title":"Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions","volume":"28","author":"Mayo-de-Las-Casas","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2022.114533_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114533_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113523","article-title":"Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy","volume":"221","author":"Ayati","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib35","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1158\/0008-5472.CAN-04-1905","article-title":"Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255","volume":"64","author":"Tracy","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114533_bib36","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.2147\/OTT.S124757","article-title":"Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin","volume":"10","author":"Hu","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2022.114533_bib37","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2022.114533_bib38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/1535-7163.MCT-16-0407","article-title":"Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer","volume":"16","author":"Kobayashi","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114533_bib39","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/fon.11.62","article-title":"Afatinib (BIBW 2992) development in non-small-cell lung cancer","volume":"7","author":"Hirsh","year":"2011","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2022.114533_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3727\/096504012X13285365944337","article-title":"The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells","volume":"19","author":"Rho","year":"2011","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2022.114533_bib41","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114533_bib42","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1038\/s41467-018-07078-0","article-title":"Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors","volume":"9","author":"Fassunke","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114533_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114533_bib44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.bbrc.2018.05.154","article-title":"Crystal structure of EGFR T790M\/C797S\/V948R in complex with EAI045","volume":"502","author":"Zhao","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2022.114533_bib45","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1039\/C8SC01262H","article-title":"Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket","volume":"9","author":"Kannan","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2022.114533_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2022.114533_bib47","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrm.2016.91","article-title":"Structural insights into the catalysis and regulation of E3 ubiquitin ligases","volume":"17","author":"Buetow","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114533_bib48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.cell.2016.03.003","article-title":"Types of ubiquitin ligases","volume":"165","author":"Morreale","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114533_bib49","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1021\/jacs.1c00990","article-title":"DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras","volume":"143","author":"Zhang","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114533_bib50","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acschembio.0c00348","article-title":"A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL","volume":"15","author":"Tong","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114533_bib51","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114533_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 ligase ligands in successful PROTACs: an Overview of syntheses and linker attachment points","volume":"9","author":"Bricelj","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112451","article-title":"Optimal linker length for small molecule PROTACs that selectively target p38alpha and p38beta for degradation","volume":"201","author":"Donoghue","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib54","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib55","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41594-020-0438-0","article-title":"Targeted protein degradation as a powerful research tool in basic biology and drug target discovery","volume":"27","author":"Wu","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114533_bib56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114533_bib57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","article-title":"ATTEC: a potential new approach to target proteinopathies","volume":"16","author":"Li","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2022.114533_bib58","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2022.114533_bib59","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","article-title":"A method for the acute and rapid degradation of endogenous proteins","volume":"171","author":"Clift","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114533_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114533_bib61","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ddr.21765","article-title":"Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti-tumor immunity in non-small cell lung cancer","volume":"82","author":"Wang","year":"2021","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2022.114533_bib62","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","article-title":"Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112781","article-title":"Discovery of potent small molecule PROTACs targeting mutant EGFR","volume":"208","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib64","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1021\/jm301365e","article-title":"Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations","volume":"55","author":"Yang","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib65","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2018.02.051","article-title":"Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs","volume":"148","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib66","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1016\/j.bmc.2018.05.039","article-title":"Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold","volume":"26","author":"Zhang","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112061","article-title":"Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)","volume":"189","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib68","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/acsmedchemlett.1c00645","article-title":"Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting del19\/T790M\/C797S mutation","volume":"13","author":"Zhang","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114533_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127167","article-title":"Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide","volume":"30","author":"He","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114533_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105605","article-title":"Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy","volume":"120","author":"Shi","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib72","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2022.114533_bib73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114533_bib74","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/molecules25040884","article-title":"Newly developed prodrugs and prodrugs in development; an insight of the recent years","volume":"25","author":"Najjar","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114533_bib75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2017.06.013","article-title":"Prodrugs in medicinal chemistry and enzyme prodrug therapies","volume":"118","author":"Walther","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2022.114533_bib76","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","article-title":"Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia","volume":"57","author":"Cheng","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2022.114533_bib77","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.1c02221","article-title":"Rational design for nitroreductase (NTR)-Responsive proteolysis targeting chimeras (PROTACs) selectively targeting tumor tissues","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib78","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1021\/acs.jmedchem.1c00649","article-title":"Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib79","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib80","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114533_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111664","article-title":"Natural products as important tyrosine kinase inhibitors","volume":"182","author":"Yin","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114533_bib82","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/ars.2015.6420","article-title":"Targeting tyrosine kinase inhibitor-resistant non-small cell lung cancer by inducing epidermal growth factor receptor degradation via methionine 790 oxidation","volume":"24","author":"Leung","year":"2016","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2022.114533_bib83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13046-019-1234-8","article-title":"Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death","volume":"38","author":"Chen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114533_bib84","article-title":"Disruptin, a cell-penetrating peptide degrader of EGFR","volume":"14","author":"Mehta","year":"2021","journal-title":"Transl. Oncogenomics"},{"key":"10.1016\/j.ejmech.2022.114533_bib85","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41392-020-00251-2","article-title":"Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth","volume":"5","author":"Yao","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2022.114533_bib86","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114533_bib87","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41467-021-23194-w","article-title":"Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:41:45Z","timestamp":1759329705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422004354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":87,"alternative-id":["S0223523422004354"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114533","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the development of EGFR degraders: PROTACs and LYTACs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114533"}}